P/E at 35.38 vs Industry's 34.06: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 35.38, slightly above the Pharmaceuticals & Biotechnology industry average of 34.06. This premium, though not extreme, suggests investors are willing to pay a bit more for the stock relative to its peers. The market capitalisation of ₹4,40,086.02 crore places it firmly in the large-cap category, reflecting its established position within the sector.

This valuation premium may be interpreted as a reflection of the company’s relative stability and growth prospects within a sector that has seen varied results. However, the premium is modest enough to warrant a closer look at the underlying performance metrics — previously rated Hold, what is Sun Pharma’s current rating? The four-parameter analysis factors in the valuation premium alongside momentum and technical indicators.

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 10.23% gain, outperforming the Sensex’s 6.34% loss during the same period. This outperformance extends to longer horizons as well, with three-year and five-year returns of 85.25% and 175.22% respectively, both significantly ahead of the Sensex’s 22.06% and 46.78% gains.

However, the short-term momentum is less robust. The stock’s one-month return is -0.60%, lagging the Sensex’s 2.35% rise, and the three-month return of 3.19% slightly trails the Sensex’s 3.56%. Year-to-date, the stock has gained 6.66%, contrasting with the Sensex’s 9.43% decline, indicating resilience in a challenging market environment. The one-week performance of 1.54% also marginally outpaces the Sensex’s 1.21% gain, while the one-day change of -0.16% is slightly behind the Sensex’s 0.50% rise.

This divergence between medium-term softness and longer-term strength raises questions about the sustainability of recent gains — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The 5% surge partially reverses a 6.45% monthly decline — the moving average configuration provides the clearest answer.

Moving Average Configuration: Bullish Across All Key Levels

Technically, Sun Pharmaceutical Industries Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning suggests a strong upward trend and a bullish technical setup. The stock is currently just 3.65% below its 52-week high of ₹1917.15, underscoring the recent strength in price action.

Moreover, the stock has recorded four consecutive days of gains, accumulating a 2.72% return in this period. This momentum, combined with the moving average alignment, indicates a sustained recovery phase rather than a short-lived bounce. The technical picture contrasts with the modest valuation premium, highlighting a stock that is regaining investor confidence after some recent volatility — should investors in Sun Pharma hold, buy more, or reconsider?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a varied set of results recently, with 35 stocks having declared results so far. Of these, 19 reported positive outcomes, 9 were flat, and 7 posted negative results. This distribution indicates a sector with pockets of strength but also areas of concern, reflecting the complex dynamics of regulatory pressures, innovation cycles, and global demand fluctuations.

Within this context, Sun Pharmaceutical Industries Ltd appears to be navigating the sector challenges relatively well, as evidenced by its valuation premium and technical strength. The stock’s ability to maintain gains and outperform the Sensex over multiple timeframes suggests it is among the more resilient large caps in the sector.

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technical indicators. While the current rating is not disclosed, the data-driven approach behind the change highlights the importance of integrating multiple analytical dimensions.

The stock’s current Mojo Score of 74.0 and large-cap market cap grade further support the view of a fundamentally sound company with solid market standing. The rating update invites investors to consider how the valuation premium and recent price momentum align with their portfolio objectives — what is the current rating?

Conclusion: A Balanced Picture of Valuation and Momentum

The data on Sun Pharmaceutical Industries Ltd presents a nuanced story. The stock trades at a slight premium to its industry peers, supported by strong long-term returns and a robust technical setup with prices above all key moving averages. Shorter-term performance shows some softness relative to the Sensex, but the recent consecutive gains and proximity to the 52-week high indicate renewed strength.

Sector results are mixed, but Sun Pharma stands out as a resilient large-cap player. The rating reassessment from Hold to its current status reflects this evolving picture, integrating valuation, performance, and technical factors. Investors may find value in analysing how these elements interact — should investors in Sun Pharma hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today